Table 2.
AEs,a suspected to be related to LHC165 or spartalizumab
| Preferred terms n (%) | LHC165 SA patients n = 21 |
LHC165 + spartalizumab patients n = 24 |
All patients N = 45 |
|||
|---|---|---|---|---|---|---|
| All grades | Grade ≥3 | All grades | Grade ≥3 | All grades | Grade ≥3 | |
| ≥1 AE | 2 (9.5) | 0 | 14 (58.3) | 0 | 16 (35.6) | 0 |
| Pyrexia | 2 (9.5) | 0 | 8 (33.3) | 0 | 10 (22.2) | 0 |
| Pruritus | 0 | 0 | 6 (25.0) | 0 | 6 (13.3) | 0 |
| Chills | 1 (4.8) | 0 | 4 (16.7) | 0 | 5 (11.1) | 0 |
| Asthenia | 0 | 0 | 2 (8.3) | 0 | 2 (4.4) | 0 |
| TRAEs leading to discontinuation | ||||||
| Pancreatitis | 0 | 0 | 1 (4.2) | 1 (4.2) | 1 (2.2) | 1 (2.2) |
MedDRA v25.0, CTCAE v4.03.
AE, adverse event; SA, single agent; TRAE, treatment-related adverse event.
a
All patients, all grades, safety set.